Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - thiomersal; selenium; vitamin b12a = hydroxocobalamin; clostridium chauvoei - formol culture; clostridium novyi type b; cla = corynebacterium pseudotuberculosis ovis; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid - misc. vaccines or anti sera - thiomersal mercury active 0.1 mg/ml; selenium mineral-selenium active 1.0 mg/ml; vitamin b12a = hydroxocobalamin vitamin-b12 active 2.0 mg/ml; clostridium chauvoei - formol culture vaccine-microbial active 0.0 u; clostridium novyi type b vaccine-microbial active 0.0 u; cla = corynebacterium pseudotuberculosis ovis vaccine-microbial active 0.0 u; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 u; clostridium septicum - toxoid vaccine-toxoid active 0.0 u; clostridium tetani - toxoid vaccine-toxoid active 0.0 u - immunotherapy - lamb | sheep | sheep ram (male) | ewe | hogget | lamb | ovine | ram | weaner | wether - black disease | blackleg | caseous lymphadenitis (cheesy gland) | enterotoxaemia (pulpy kidney) | malignant oedema | swelled head | tetanus | vitamin b12 deficiency | white muscle disease | anaemia | clostridium perfringens type d | cobalt deficiency | selenium deficiency | stiff lamb disease | subacute enzootic muscular dys | tetanus vaccination

Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - thiomersal; bordetella bronchiseptica (inactivated cell free extract - parenteral liquid/solution/suspension - thiomersal mercury active 0.1 mg/ml; bordetella bronchiseptica (inactivated cell free extract vaccine-microbial active 0.0 u - immunotherapy - dog | bitch | castrate | puppy - bordetella spp. | bordetella bronchiseptica

Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - thiomersal; selenium as sodium selenate; clostridium chauvoei - toxoid; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid - parenteral liquid/solution/suspension - thiomersal mercury active 0.13 mg/ml; selenium as sodium selenate mineral-selenium active 0.5 mg/ml; clostridium chauvoei - toxoid vaccine-toxoid active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 3.5 iu/ml; clostridium perfringens type d toxoid vaccine-toxoid active 5.0 iu/ml; clostridium septicum - toxoid vaccine-toxoid active 2.5 iu/ml; clostridium tetani - toxoid vaccine-toxoid active 2.5 iu/ml - immunotherapy - lamb | ovine - black disease | blackleg | enterotoxaemia (pulpy kidney) | malignant oedema | selenium deficiency | tetanus | unthriftiness | white muscle disease | clostridium perfringens type d | ill - thrift | selenium deficiency | selenium responsive ill-thrift | stiff lamb disease | subacute enzootic muscular dys | tetanus vaccination | white muscle disease

Јужноафричка Република - Енглески - South African Health Products Regulatory Authority (SAHPRA)

sad -

Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - feline immunodeficiency virus(petaluma strain)inactive; neomycin; polymyxin b; thiomersal - misc. vaccines or anti sera - feline immunodeficiency virus(petaluma strain)inactive vaccine-virus active 0.0 p; neomycin antibiotic other 0.0 undefined; polymyxin b antibiotic other 0.0 undefined; thiomersal mercury other 0.0 undefined - immunotherapy - cat - over 8 weeks of age - fiv immunisation

Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - thiomersal; selenium; clostridium chauvoei - toxoid; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; tetanus = clostridium tetani - parenteral liquid/solution/suspension - thiomersal mercury active 0.1 mg/ml; selenium mineral-selenium active 1.0 mg/ml; clostridium chauvoei - toxoid vaccine-toxoid active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 0.0 p; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 p; clostridium septicum - toxoid vaccine-toxoid active 0.0 p; tetanus = clostridium tetani vaccine-toxoid active 0.0 p - immunotherapy - lamb | sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - black disease | blackleg | enterotoxaemia (pulpy kidney) | malignant oedema | tetanus | white muscle disease | clostridium perfringens type d | selenium deficiency | stiff lamb disease | subacute enzootic muscular dys | tetanus vaccination

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 10 microgram/ml - injection, suspension - excipient ingredients: aluminium; borax; sodium chloride; water for injections - h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who ar at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 10 microgram/ml - injection, suspension - excipient ingredients: borax; sodium chloride; aluminium; water for injections - h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who ar at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 40 microgram/ml - injection, suspension - excipient ingredients: borax; sodium chloride; aluminium; water for injections - h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who ar at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.